FDA panel split on safety of testosterone drug

Published



WASHINGTON (AP) — Federal health experts issued a split opinion Thursday on whether a long-acting testosterone injection from Endo Health Solutions is safe.

A Food and Drug Administration panel voted 9-9 on the safety of Endo’s Aveed, a drug designed to be injected once every 10 weeks to boost testosterone in men with abnormally low levels. The FDA is not required to follow the group’s advice, though it often does.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.